{"protocolSection":{"identificationModule":{"nctId":"NCT05781880","orgStudyIdInfo":{"id":"NBOTIP"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Normobaric Hyperoxia Stabilizing Ischemic Penumbra","officialTitle":"Efficiency and Safety Evaluation of Normobaric Hyperoxia Stabilizing the Penumbra in Patients With Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2023-04","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-03-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-11-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-03-06","studyFirstSubmitQcDate":"2023-03-22","studyFirstPostDateStruct":{"date":"2023-03-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-04-17","lastUpdatePostDateStruct":{"date":"2023-04-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Ji Xunming,MD,PhD","investigatorTitle":"Professor","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Ji Xunming,MD,PhD","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To investigate the safety and efficacy of normobaric hyperoxia (NBO) stabilizing penumbra in acute ischemic stroke patients.","detailedDescription":"All the enrolled patients were randomly assigned to NBO and control group. NBO group will be given 100% oxygen ( (10L/min for 4h) via a storage oxygen face mask and control group will be given oxygen using nasal oxygen(2L/min for 4h) ."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Normobaric Hyperoxia","Acute ischemic stroke","penumbra"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"Outcomes indexes will be assessed by trained neurologists or neuroradiologists who are blinded to the research content or patient grouping.","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":78,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NBO group","type":"EXPERIMENTAL","description":"Normobaric hyperoxia (NBO) oxygen group will be given 100% oxgen (10L/min for 4h) via a face mask.","interventionNames":["Other: Oxygen 100%"]},{"label":"Control group","type":"PLACEBO_COMPARATOR","description":"Control group will be given nasal oxygen (2L/min for 4h）. All other therapy measures are the same as experimental group.","interventionNames":["Other: Oxygen 100%"]}],"interventions":[{"type":"OTHER","name":"Oxygen 100%","description":"NBO therapy were given 100% oxygen via a face mask (10L/min for 4h)","armGroupLabels":["Control group","NBO group"],"otherNames":["Normobaric hyperoxia"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"changing of penumbra volume from baseline","description":"the comparison of ratio of 4h following randomizing and baseline for penumbra volume between NBO and control group","timeFrame":"Day 0"}],"secondaryOutcomes":[{"measure":"penumbra volume at 4h following randomizing","description":"the absolute penumbra volume comparison between NBO and control group","timeFrame":"Day 0"},{"measure":"volume of core infarction at 4h following randomizing","description":"core infarction volume comparison between NBO and control group","timeFrame":"Day 0"},{"measure":"volume of hypoperfusion region hypoperfusion at 4h following randomizing","description":"the volume of hypoperfusion region hypoperfusion comparison between NBO and control group","timeFrame":"Day 0"},{"measure":"National Institutes of Health Stroke Scale (NIHSS) score at 24h following randomizing","description":"the comparison of NIHSS score between NBO and control group; NIHSS score ranges from 0 to 42, and higher scores mean a worse outcome.","timeFrame":"Day 1"},{"measure":"modified rankin scale (mRS) score at 90 days following randomizing","description":"the mRS score comparison between NBO and control group; mRS score ranges from 0 to 5, and the higher score means a worse outcome.","timeFrame":"Month 3"},{"measure":"Barthel Index at 90 days following randomizing","description":"the comparison of Barthel Index between NBO and control group","timeFrame":"Month 3"},{"measure":"EQ-5D index at 90 days following randomizing","description":"the comparison of EQ-5D index between NBO and control group","timeFrame":"Month 3"},{"measure":"BBB injured biomarkers at baseline and 24h following randomizing","description":"the levels of BBB injured biomarkers comparison between NBO and control group","timeFrame":"Day 1"},{"measure":"Cerebral oxygen concentration at baseline and 4h following randomizing","description":"the levels of cerebral oxygen comparison between NBO and control group","timeFrame":"Day 0"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Age≥18岁\n* The signs and symptoms are consistent with anterior circulation infarction, and baseline NIHSS score：6-20\n* Level of consciousness on admission：0-1\n* mRS score before stroke: 0-1\n* Patients who did not receive revascularization therapy\n* The time from onset (finally normal) to randomization is less than 24h\n* Patients who signed informed consent\n* CTA or MRA confirmed internal carotid artery occlusion or M1/M2 segment occlusion of middle cerebral artery\n* The low-perfusion area with Tmax\\>6s was larger than the core infarction, and the mismatch ratio was greater than or equal to 1.8.\n\nExclusion Criteria:\n\n* Evidence of rapid improvement in neurological function and NIHSS score \\<6, or spontaneous recanalization before randomization\n* The disease affecting assessment of baseline NIHSS score (dementia, epilepsy, neuromuscular disease, or psychiatric disease)\n* Symptoms suggesting subarachnoid hemorrhage (even if CT scan is normal)\n* Combined with the history, cerebral embolism due to sepsis or infective endocarditis was suspected\n* Active or chronic obstructive pulmonary disease, pulmonary fibrosis, pneumonia, pleural effusion, acute respiratory distress syndrome, irregular breathing\n* It is necessary to inhale (\\>3L/min) oxygen to maintain peripheral arterial oxygen saturation (SaO2\\>95%)\n* Anemia or polycythemia vera or other conditions needing emergency oxygen patients\n* Patients with upper gastrointestinal bleeding or nausea and vomiting can not complete inhalation oxygen using face mask\n* Baseline blood glucose \\<2.78mmol/L or \\>22.2mmol/L\n* Baseline platelet count \\<50×109/L\n* Hereditary or acquired bleeding tendency, lack of coagulation factor, recent oral anticoagulant INR\\>3 or PPT more than 3 times\n* Unstable vital signs (heart rate ≤50 beats/min or ≥120 beats/min, oxygen saturation ≤90%, R≥30 beats/min or ≤10 beats/min)\n* Hypertension not controlled by medication: systolic blood pressure ≥185mmHg, or diastolic blood pressure ≥110mmHg\n* Acute myocardial infarction suspected\n* Pregnancy,\n* Life expectancy \\<90 days\n* Heart, liver and kidney failure\n* Magnetic resonance contraindications\n* Claustrophobia\n* Allergic to contrast media\n* Participating in other drug or device research","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Zhifeng Qi, Ph.D","role":"CONTACT","phone":"010-83199236","email":"qizhifeng@xwh.ccmu.edu.cn"},{"name":"Shuhua Yuan, Ph.D","role":"CONTACT","phone":"15538260193","email":"750495168@qq.com"}],"overallOfficials":[{"name":"Xunming Ji, MD","affiliation":"Xuanwu Hospital of Capital Medical University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Xuanwu Hospital of Capital Medical University","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100032","country":"China","contacts":[{"name":"Shuhua Yuan, Ph.D","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"},{"id":"D000018496","term":"Hyperoxia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000012818","term":"Signs and Symptoms, Respiratory"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M20290","name":"Hyperoxia","asFound":"Hyperoxia","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M15313","name":"Signs and Symptoms, Respiratory","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}